Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of Type-2 inflammation over inhibition of either pathway alone

Publication date: Available online 30 September 2016
Source:Journal of Allergy and Clinical Immunology
Author(s): Vladimir Ramirez-Carrozzi, Arivazhagan Sambandam, Meijuan Zhou, Donghong Yan, Jing Kang, Xiumin Wu, Eric Suto, Miriam Baca, Cary Austin, Min Xu, Wyne P. Lee, Rajita Pappu

Teaser

Both IL-33 and IL-13 promote Type-2 inflammation and are implicated in the pathogenesis of asthma. Blocking both pathways together leads to a greater suppression of Type-2 inflammation over inhibiting either pathway alone.


from #ENT via xlomafota13 on Inoreader http://ift.tt/2dE0ThT
via IFTTT